Biomerica annual stock-based compensation
2018
2019
2021
2022
2023
2024
2025
2026
Biomerica Stock-Based Compensation Growth & History (BMRA)
Biomerica's stock-based compensation was $476,000 for fiscal 2026.
View full Biomerica company overviewBiomerica annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-05-31 | $476,000 | $16,000 | +3.48% |
| 2025 | 2025-05-31 | $460,000 | −$377,000 | −45.04% |
| 2024 | 2024-05-31 | $837,000 | −$348,000 | −29.37% |
| 2023 | 2023-05-31 | $1.2M | −$75,000 | −5.95% |
| 2022 | 2022-05-31 | $1.3M | −$95,000 | −7.01% |
| 2021 | 2021-05-31 | $1.4M | — | — |
| 2019 | 2019-05-31 | $151,224 | $132,751 | +718.62% |
| 2018 | 2018-05-31 | $18,473 | — | — |
Biomerica quarterly stock-based compensation
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q4 2026 | 2026-05-31 | $91,000 | −$17,000 | −15.74% |
| Q3 2026 | 2026-02-28 | $135,000 | $15,000 | +12.50% |
| Q2 2026 | 2025-11-30 | $117,000 | −$38,000 | −24.52% |
| Q1 2026 | 2025-08-31 | $133,000 | $56,000 | +72.73% |
| Q4 2025 | 2025-05-31 | $108,000 | −$96,000 | −47.06% |
| Q3 2025 | 2025-02-28 | $120,000 | −$221,000 | −64.81% |
| Q2 2025 | 2024-11-30 | $155,000 | $33,000 | +27.05% |
| Q1 2025 | 2024-08-31 | $77,000 | −$93,000 | −54.71% |
| Q4 2024 | 2024-05-31 | $204,000 | $25,000 | +13.97% |
| Q3 2024 | 2024-02-29 | $341,000 | −$43,000 | −11.20% |
| Q2 2024 | 2023-11-30 | $122,000 | −$196,000 | −61.64% |
| Q1 2024 | 2023-08-31 | $170,000 | −$134,000 | −44.08% |
| Q4 2023 | 2023-05-31 | $179,000 | −$121,632 | −40.46% |
| Q3 2023 | 2023-02-28 | $384,000 | $58,651 | +18.03% |
| Q2 2023 | 2022-11-30 | $318,000 | $3,603 | +1.15% |
| Q1 2023 | 2022-08-31 | $304,000 | −$15,622 | −4.89% |
| Q4 2022 | 2022-05-31 | $300,632 | — | — |
| Q3 2022 | 2022-02-28 | $325,349 | — | — |
| Q2 2022 | 2021-11-30 | $314,397 | — | — |
| Q1 2022 | 2021-08-31 | $319,622 | — | — |
Biomerica stock-based compensation trends
Over the last five fiscal years, Biomerica's stock-based compensation decreased from $1.4M to $476,000, a change of −$879,000. The latest reported quarter, Q4 2026, shows $91,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Biomerica source filings ↗